Jubilant Biosys to expand its footprint in Europe, add drug discovery & preclinical development capabilities

New Delhi: Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited and Pierre Fabre SA are entering in a strategic partnership.

Pursuant to this, JBIRSPL would acquire 80% equity capital in Jasmin (new company incorporated in France, as a Société par Actions Simplifiée (SAS), 100% owned by Pierre Fabre). Jasmin shall acquire Pierre Fabre’s R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France upon closing of the transaction.

This strategic partnership will enable Jubilant Biosys Limited to expand its footprint in Europe in areas like Biologics (mAbs) and Antibody Drug Conjugate (ADC), in addition to its existing services including integrated drug discovery services from India.

Speaking on the announcement, Giuliano Perfetti, CEO & Managing Director, Jubilant Biosys Limited said, “We are excited to embark on this new strategic partnership with Pierre Fabre. The facility in Saint Julien will serve as our European Centre of Excellence for Biologics and ADCs, located in the heart of Europe. This will enhance our footprint and collaboration with both biotech and large pharma companies in Europe and the USA.”

“By combining the scientific expertise in Biologics and ADCs at our Saint Julien site with the capabilities of 1,200 scientists at our Centres of Excellence for Drug Discovery, Chemistry and CDMO in India, we can develop a unique delivery model tailored to our customers’ needs, driving our company’s growth. With this strategic move, Jubilant Biosys continues to strengthen its position as a preferred “CRDMO Partner in Science,” committed to delivering innovative solutions to our customers,” added Perfetti.